Company Overview
Annovis Bio, Inc. operates as a clinical stage drug platform company focused on developing therapeutics to treat neurodegeneration within the United States. The company's lead product candidate, Buntanetap, is currently advancing through phase 2/3 clinical trials for the treatment of Alzheimer's disease and phase 3 trials for Parkinson's disease, alongside additional phase 2 clinical development efforts. This biotechnology entity functions within the broader Healthcare sector and the specific Biotechnology industry, positioning itself to address significant unmet medical needs in neurological disorders. With a market capitalization of $57.56M and an employee count of 7, the company maintains a highly lean operational structure typical of early-stage biotech firms. The combination of a market cap under $60 million and the absence of reported annual revenue indicates that the company is in a pre-commercialization phase, where value is derived primarily from intellectual property and clinical data rather than sales figures.
Financial Health
The company reports no annual revenue for the trailing twelve months, while the net income for the same period stands at $-28,854,196, reflecting a substantial deficit that highlights the high cost structure associated with late-stage clinical trials. EBITDA is not available for the trailing twelve months, which further obscures the direct correlation between operational revenue and earnings before interest, taxes, depreciation, and amortization due to the lack of positive cash generation from sales. Free cash flow is recorded at $-15,183,042, indicating that the company is burning cash to fund its research and development activities without yet generating sufficient operational cash inflows. All three margin metrics—gross margin, operating margin, and profit margin—are listed as 0.0%, a standard characteristic for biotechnology companies in clinical development that have not yet achieved commercial product sales to calculate meaningful profitability ratios. The company holds $19.53M in cash, whereas debt is not available, suggesting a balance sheet focused on liquidity retention rather than leveraging for growth. This cash position provides a buffer against the ongoing cash burn, though the absence of a debt-to-equity ratio implies that traditional leverage metrics are not applicable or disclosed. The current ratio is 5.80, which indicates a robust short-term liquidity position where current assets significantly exceed current liabilities, ensuring the ability to meet obligations despite the lack of operating cash flow. Return on Equity is -220.6% and return on assets is -106.0%, metrics that reveal that the company's existing equity and asset base are currently generating losses rather than returns, which is typical for firms in the clinical stage before product launch.
Valuation Assessment
The trailing P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed as -1.88, a negative figure that implies the market is pricing in continued losses or a turnaround scenario rather than current profitability. The price-to-book ratio is 3.27, indicating that the market values the company at more than three times its book value, a premium often attributed to the potential value of the company's pipeline assets and intellectual property. Neither the price-to-sales ratio nor the EV/EBITDA is available for analysis, as the absence of revenue and positive earnings precludes the use of these standard valuation multiples for biotechnology firms in development. The stock has traded between a 52-week low of $1.11 and a 52-week high of $5.50, with the current market cap of $57.56M suggesting a valuation that fluctuates significantly based on clinical trial milestones and market sentiment rather than earnings multiples. The beta is 1.31, which means the stock's price volatility is 31% higher than the broader market, reflecting the high-risk nature of investing in clinical-stage biotechnology where price swings are driven by regulatory and scientific outcomes.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available, as the company has not yet generated commercial revenue to calculate growth rates, meaning there is no historical data to compare against for a forward-looking growth trajectory. Since the company does not pay a dividend, the dividend yield is not available and the payout ratio is 0.0%, indicating that all available cash and any future earnings will be reinvested directly into research and development rather than distributed to shareholders. The 0.0% payout ratio is sustainable in the context of a loss-making company because there are no dividends to distribute, and the primary financial strategy involves capitalizing on the company's cash reserves to extend its runway for clinical trials. Overall, the growth and income profile is characterized by a complete reliance on capital markets for funding and a total absence of current income generation or dividend distributions, as the company remains in the clinical development phase of its lifecycle.